{"data":{"id":"10.6084/m9.figshare.1157386","type":"dois","attributes":{"doi":"10.6084/m9.figshare.1157386","prefix":"10.6084","suffix":"m9.figshare.1157386","identifiers":[],"alternateIdentifiers":[],"creators":[{"name":"Ramirez, Jorge H","nameType":"Personal","givenName":"Jorge H","familyName":"Ramirez","affiliation":[],"nameIdentifiers":[{"schemeUri":"https://orcid.org","nameIdentifier":"https://orcid.org/0000-0001-6176-2816","nameIdentifierScheme":"ORCID"}]}],"titles":[{"title":"The pharmacology of statins in humans: a critical analysis"}],"publisher":"figshare","container":{},"publicationYear":2014,"subjects":[{"subject":"Statistics"},{"subject":"FOS: Mathematics","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Mathematics","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Medicine"},{"subject":"Diseases"},{"subject":"Pharmacology"}],"contributors":[],"dates":[{"date":"2014-09-01","dateType":"Created"},{"date":"2015-12-02","dateType":"Updated"},{"date":"2014","dateType":"Issued"}],"language":null,"types":{"ris":"DATA","bibtex":"misc","citeproc":"dataset","schemaOrg":"Dataset","resourceType":"Dataset","resourceTypeGeneral":"Dataset"},"relatedIdentifiers":[],"relatedItems":[],"sizes":["634689 Bytes"],"formats":[],"version":null,"rightsList":[{"rights":"Creative Commons Attribution 4.0 International","rightsUri":"https://creativecommons.org/licenses/by/4.0/legalcode","schemeUri":"https://spdx.org/licenses/","rightsIdentifier":"cc-by-4.0","rightsIdentifierScheme":"SPDX"}],"descriptions":[{"description":"\u003cstrong\u003eTable 1.\u003c/strong\u003e Reanalysis of rosuvastatin serious adverse events. \u003cstrong\u003eTable 2.\u003c/strong\u003e Reanalysis of rosuvastatin non-serious adverse events. \u003cstrong\u003eStatistical analysis: Chi-square\u003c/strong\u003e \u003cstrong\u003e_________________________________\u003cbr\u003e \u003c/strong\u003e \u003cstrong\u003eDatabases: Open (worldwide) - comments allowed\u003c/strong\u003e \u003cstrong\u003e\u003cbr\u003e1st URL:\u003c/strong\u003e Google Spreadsheet - Analysis of the JUPITER trial (rosuvastatin) - NCT00239681 \u003cstrong\u003e2nd URL:\u003c/strong\u003e Google Spreadsheet - Statin registered studies at ClinicalTrials.gov and WHO ICTRP \u003cstrong\u003e3rd URL:\u003c/strong\u003e JUPITER complete database downloaded from ClinicalTrials.gov ____________________________ \u003cstrong\u003eComments about rosuvastatin JUPITER clinical trial\u003c/strong\u003e \u003cstrong\u003e1. Not all adverse drug reactions are included in Tables 1 and 2.\u003c/strong\u003e \u003cstrong\u003e2. Adverse events appear to be much higher than 18%. (1)\u003c/strong\u003e \u003cstrong\u003e3. Results available at ClinicalTrials.gov for the JUPITER study are not consistent with publications reporting the results of this trial.\u003c/strong\u003e http://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00239681 For example: Discordance between results reported in the number of patients diagnosed with diabetes mellitus. 1. ClinicalTrials.gov: Placebo=13; Rosuvastatin=14 | 2. Article (PMID: 22883507): Placebo=216; Rosuvastatin=270) \u003cstrong\u003e4. Primary outcome was modified in the registry history available at ClinicalTrials.gov\u003c/strong\u003e http://clinicaltrials.gov/archive/NCT00239681/2014_03_21/changes \u003cstrong\u003e5. It is not clear why this study was terminated.\u003c/strong\u003e March 13, 2008.\u003cbr\u003e\u003cem\u003e\"Independent Data Monitoring Committee for JUPITER met and agreed that the studyshould continue as planned.\"\u003c/em\u003e April 2, 2008.\u003cbr\u003e\u003cem\u003e\"AstraZeneca announced it has decided to stop the CRESTOR JUPITER clinicalstudy early based on a recommendation from an Independent Data Monitoring Boardand the JUPITER Steering Committee, which met on March 29, 2008. The study willbe stopped early because there is unequivocal evidence of a reduction incardiovascular morbidity and mortality amongst patients who received CRESTOR when compared to placebo.\"\u003c/em\u003e http://clinicaltrials.gov/archive/NCT00239681/2008_04_02/changes \u003cstrong\u003eReferences\u003c/strong\u003e 1. Should people at low risk of cardiovascular disease take a statin? BMJ 2014; 348:g3329","descriptionType":"Abstract"}],"geoLocations":[],"fundingReferences":[],"xml":"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","url":"https://figshare.com/articles/dataset/The_pharmacology_of_statins_in_humans_a_critical_analysis/1157386","contentUrl":null,"metadataVersion":3,"schemaVersion":"http://datacite.org/schema/kernel-4","source":"mds","isActive":true,"state":"findable","reason":null,"viewCount":0,"viewsOverTime":[],"downloadCount":0,"downloadsOverTime":[],"referenceCount":0,"citationCount":0,"citationsOverTime":[],"partCount":0,"partOfCount":0,"versionCount":0,"versionOfCount":0,"created":"2014-09-01T13:06:23.000Z","registered":"2014-09-01T13:06:24.000Z","published":"2014","updated":"2020-09-04T21:38:26.000Z"},"relationships":{"client":{"data":{"id":"figshare.ars","type":"clients"}},"provider":{"data":{"id":"otjm","type":"providers"}},"media":{"data":{"id":"10.6084/m9.figshare.1157386","type":"media"}},"references":{"data":[]},"citations":{"data":[]},"parts":{"data":[]},"partOf":{"data":[]},"versions":{"data":[]},"versionOf":{"data":[]}}}}